Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor κB Signaling Pathway in Myeloma Bone Disease.
10.3881/j.issn.1000-503X.13727
- Author:
Yan FENG
1
;
Wen-Jiao TANG
1
;
Zhong-Qing ZOU
1
;
Jian CUI
1
;
Li ZHANG
1
;
Ting NIU
1
Author Information
1. Institute of Hematology,Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China.
- Publication Type:Review
- Keywords:
multiple myeloma;
myeloma bone disease;
receptor activator of nuclear factor κB ligand
- MeSH:
Bone Diseases/metabolism*;
Humans;
Ligands;
Multiple Myeloma/metabolism*;
NF-kappa B/metabolism*;
Quality of Life;
RANK Ligand/metabolism*;
Receptor Activator of Nuclear Factor-kappa B;
Signal Transduction
- From:
Acta Academiae Medicinae Sinicae
2022;44(4):686-692
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma is an incurable malignant disease characterized by proliferation of clonal plasma cells in the bone marrow.About 90% of the patients with multiple myeloma develop myeloma bone disease(MBD),which seriously affects the quality of life and prognosis of the patients.Traditional therapies for MBD include bisphosphonates,radiotherapy,and surgery.The recent studies have confirmed that the receptor activator of nuclear factor κB ligand (RANKL)-receptor activator of nuclear factor κB(RANK) signaling pathway plays a key role in MBD,providing a new therapeutic target for MBD.This review summarized the role of RANKL-RANK signaling pathway in the pathogenesis of MBD and the advance in the targeted therapy.
